Myocardial Infarction Genes (MI-GENES) Study
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 45 - 70 |
| Updated: | 5/4/2016 |
| Start Date: | July 2013 |
| End Date: | November 2014 |
Myocardial Infarction Genes (MI-GENES) Study - Using Genomic Data to Refine Risk Assessment for Heart Attack
This study is being done to better understand how genetic information might improve
assessment of heart attack risk.
assessment of heart attack risk.
This study aims to randomize patients to 2 arms. The first arm will receive the conventional
Framingham risk score for coronary heart disease while the intervention arm will receive the
genetics-informed risk for coronary artery disease.
The investigators will assess baseline blood lipid levels and follow the 2 arms up to 6
months after randomization. Primary endpoint is change in LDL levels between the 2 arms.
Secondary outcomes include blood pressure control, weight, smoking cessation, and other
lifestyle modifications.
This trial will help us understand whether coronary artery disease risk derived from genetic
information would have a significant impact on patients' perception of coronary artery
disease risk and motivate healthy lifestyle modifications that reduce their long term risk.
Framingham risk score for coronary heart disease while the intervention arm will receive the
genetics-informed risk for coronary artery disease.
The investigators will assess baseline blood lipid levels and follow the 2 arms up to 6
months after randomization. Primary endpoint is change in LDL levels between the 2 arms.
Secondary outcomes include blood pressure control, weight, smoking cessation, and other
lifestyle modifications.
This trial will help us understand whether coronary artery disease risk derived from genetic
information would have a significant impact on patients' perception of coronary artery
disease risk and motivate healthy lifestyle modifications that reduce their long term risk.
Inclusion Criteria:
- Patients between the ages of 45-70 years
- Patients who have participated in the Mayo Clinic Biobank or a previous research
study at Mayo Clinic
- Patients who live in Southeast Minnesota
Exclusion Criteria:
- Taking statin or other lipid lowering medications
- Patients with a history of myocardial infarction, coronary artery disease, or other
atherosclerotic medical conditions
We found this trial at
1
site
Click here to add this to my saved trials
